Inclusion Criteria

Concurrent Medication:

Allowed:

• Erythropoietin.

Concurrent Treatment:

Allowed:

• Transfusion.

Patients must have:

• Progressive HIV disease.
• At least 24 weeks prior cumulative nucleoside analog antiretroviral monotherapy or combination therapy.

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms or conditions are excluded:

• Active malignancy requiring chemotherapy.
• Currently receiving therapy in an ACTG primary therapy or salvage protocol who have NOT met an endpoint on that study.
• Known intolerance (other than hematologic) or toxicity to ddI, AZT, or NVP at the doses used in this study.

Concurrent Medication:

Excluded (unless exemption made by study chair):

• Oral anticoagulants (warfarin, dicumarol).
• Oral contraceptives.
• Digitalis glycosides.
• Phenytoin.
• Theophylline.

Patients with the following prior conditions are excluded:

• History of clinical pancreatitis.
• History of grade 2 or worse peripheral neuropathy.

Prior Treatment:

Excluded:

• Acute treatment for a serious bacterial, viral, or opportunistic infection within 14 days prior to study entry.